Luo, Yuan-Xi
Matniyaz, Yusanjan
Tang, Yu-Xian
Xue, Yun-Xing
Jiang, Yi
Pan, Ke
Lv, Zhi-Kang
Fan, Zhi-Wei
Wang, Kuo
Zhang, Hai-Tao
Zhang, He
Wang, Wen-Zhe
Pan, Tuo
Wang, Dong-Jin
Fan, Fu-Dong
Funding for this research was provided by:
the National Natural Science Foundation of China (No.81970401)
Jiangsu Provincial Key Medical Discipline (No. ZDXKA2016019)
The Health Commission of Nanjing (YKK22096)
Article History
Received: 24 October 2023
Accepted: 11 March 2024
First Online: 19 March 2024
Declarations
:
: The study and protocol received approval from the Institutional Review Board (IRB) of Nanjing Drum Tower Hospital (approval number: 2020-293-02). The study adhered to the ethical principles stated in the “Declaration of Helsinki”, the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guideline, as well as the “Quality Management Standards for Drug Clinical Trials” and “Medical Devices Clinical Trial Quality Management Standards” established by the Chinese Food and Drug Administration (CFDA). Additionally, it complied with the “Ethical Review Measures for Biomedical Research Involving Humans” issued by the National Health Commission of China, along with other pertinent national laws and regulations. Prior to their inclusion in the study, the study participant or a legally authorized representative provided informed consent.
: Not applicable.
: The authors have no relevant financial or non-financial interests to disclose.